biomarker discovery, was recently selected Awardee of the Carcinogenic Exposure Meter Quickfire Challenge. The Challenge was launched by Johnson & Johnson Innovation, the Lung Cancer Initiative (LCI) at Johnson & Johnson, and Janssen in an effort to help reduce the tobacco epidemic. 

As part of the collaboration, Janssen will fund the assessment of clinical PEx-samples to identify biomarker categories that potentially can detect carcinogenic damage resulting from tobacco exposure. 

Erik Ekbo, CEO of PExA comments on the agreement:
“Collaborating with one of the world’s most innovative pharmaceutical companies provides a significant step forward in our transformation journey to deliver novel solutions suitable for point-of-care testing.” 

For further information, please contact:
Erik Ekbo, CEO
Phone: +46 723-92 30 30
E-mail: erik@pexa.se

This information is information which PExA AB is obligated to publish under the EU Market Abuse Regulation. The information was provided through the agency of above contact person, for publication on October 2 2019.

PExA AB (556956-9246) develops and markets a research instrument with associated products and services to lung researchers for simple and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PExA can be used to detect lung diseases at an early stage. The sample can be likened to a “blood test for the small airways”. The aim is to facilitate the development of reliable and more individualised diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventors, key employees, business angels and GU Ventures. PExA’s B share is listed on Spotlight Stock Market